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Objective: The efﬁcacy of psychodynamic
therapies for depression remains open to
debate because of a paucity of high-quality
studies. The authors compared the efﬁcacy
of psychodynamic therapy with that of
cognitive-behavioral therapy (CBT), hypoth-
esizing nonsigniﬁcant differences and the
noninferiority of psychodynamic therapy
relative to CBT.
Method: A total of 341 adults who met
DSM-IV criteria for a major depressive
episode and had Hamilton Depression
Rating Scale (HAM-D) scores $14 were
randomly assigned to 16 sessions of in-
dividual manualized CBT or short-term
psychodynamic supportive therapy. Severely
depressed patients (HAM-D score .24)
also received antidepressant medication
according to protocol. The primary out-
come measure was posttreatment remis-
sion rate (HAM-D score #7). Secondary
outcome measures included mean post-
treatment HAM-D score and patient-rated
depression score and 1-year follow-up
outcomes. Data were analyzed with gen-
eralized estimating equations and mixed-
model analysesusing intent-to-treat samples.
Noninferiority margins were prespeciﬁed as
an odds ratio of 0.49 for remission rates and
a Cohen’s d value of 0.30 for continuous
outcome measures.
Results: No statistically signiﬁcant treat-
ment differences were found for any of the
outcomemeasures. The average posttreat-
ment remission rate was 22.7%. Noninfer-
iority was shown for posttreatment HAM-D
and patient-rated depression scores but
could not be demonstrated for posttreat-
ment remission rates or any of the follow-
up measures.
Conclusions: The ﬁndings extend the
evidence base of psychodynamic therapy
for depression but also indicate that time-
limited treatment is insufﬁcient for a sub-
stantial number of patients encountered
in psychiatric outpatient clinics.
(Am J Psychiatry 2013; 170:1041–1050)
Major depressive disorder is a highly prevalent
mental disorder, substantially debilitating patients and
imposing a tremendous ﬁnancial burden on society (1, 2).
Patients seeking treatment for depression typically are
offered antidepressant medication or psychotherapy alone
or in combination (3). Given that antidepressants may not
be as speciﬁcally efﬁcacious as was previously believed
(4–6), treatment guidelines increasingly advocate the option
of psychotherapy for mild to moderate depression (7, 8).
However, efﬁcacy research with respect to psychother-
apy for depression needs to be broadened for two reasons.
First, the efﬁcacy of psychodynamic therapy remains
controversial because of a lack of adequately conducted
trials (7–10). Second, while different psychotherapeutic
approaches for depression are considered equally efﬁca-
cious by many (11), high-quality studies directly compar-
ing psychotherapies for depression are rare (12), and the
literature is dominated by superiority trials designed to
show signiﬁcant differences between conditions, which
cannot demonstrate equal efﬁcacy (13).
We report the results of a randomized clinical tri-
al comparing psychodynamic therapy with cognitive-
behavioral therapy (CBT) in patients seeking treatment
for a major depressive episode in psychiatric outpatient
clinics (the study protocol was described previously [14]).
We ﬁrst examined whether treatment outcomes differed
signiﬁcantly, and in case of nonsigniﬁcant differences,
we examined whether psychodynamic therapy was
noninferior to CBT. We hypothesized that there would
be 1) no signiﬁcant differences between the modalities
at the posttreatment assessment and 1-year follow-up
and 2) noninferiority of psychodynamic therapy rela-
tive to CBT at the posttreatment assessment and 1-year
follow-up.
Method
Design
This study was a randomized clinical trial with an allocation
ratio of 1:1 for CBT and psychodynamic therapy. The study
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Am J Psychiatry 170:9, September 2013 ajp.psychiatryonline.org 1041
design was approved by the Dutch Union of Medical Ethics Trial
Committees for mental health organizations.
Participants
Participants were referred by their general practitioner to one of
three psychiatric outpatient clinics in Amsterdam. Inclusion criteria
were presence of a major depressive episode according to DSM-IV
criteria, as assessed with the Mini-International Neuropsychiatric
Interview–Plus (15); a Hamilton Depression Rating Scale (HAM-D
[16]) score $14; age 18–65 years; and written informed consent
after receiving a complete description of the study.
Exclusion criteria included presence of psychotic symptoms
or bipolar disorder, severe suicidality warranting immediate in-
tensive treatment or hospitalization, substance misuse or abuse
in the past 6 months, pregnancy, inability to meet trial demands,
and use of psychotropic or other medications that might inﬂu-
ence mental functions. Patients on an antidepressant regimen
were included only if the medication they were currently taking
was judged to be inefﬁcacious by both the patient and the intake
psychiatrist. If so, the medication was tapered off under medical
supervision, and baseline assessment took place after a washout
period of at least 1 week after the medication was completely
stopped (16/25 of these patients subsequently restarted medica-
tion during the study).
Interventions
Both psychotherapies comprised 16 individual sessions within
22 weeks and were conducted according to published treatment
manuals (17, 18). Additionally, both were suitable for application in
a broad group of patients, including those of a non-Northwest
European (immigrant) cultural background. CBT was based on
the principles described by Beck (19) and included behavioral
activation and cognitive restructuring according to a session-by-
session protocol with homework assignments. Short-term psycho-
dynamic supportive psychotherapy (18, 20–24) was used to
represent the psychodynamic intervention. This modality involved
an open patient-therapist dialogue that used supportive and
insight-facilitating techniques to address the emotional back-
ground of the depressive symptoms by discussing current relation-
ships, internalized past relationships, and intrapersonal patterns.
Psychotherapists in both treatment conditions were psy-
chiatrists or psychologists with at least a master’s degree who
completed either a 3-day course in short-term psychodynamic
supportive psychotherapy or a 100-hour basic CBT training course
accredited by the Dutch Association for Behavioral and Cognitive
Therapy. Moreover, all therapists adequately conducted at least
one intensively supervised therapy case in accordance with the
relevant treatment manual as judged by a study supervisor.
Although no formal assessments were conducted, manual ﬁdelity
was checked by means of biweekly supervision sessions, chaired
by a study supervisor, in which audiotaped material was dis-
cussed. All study supervisors were registered supervisors with
either the Dutch Association of Psychoanalytic Psychotherapy
(one supervisor was in training) or the Dutch Association for
Behavioral and Cognitive Therapy. Differences in the mean
number of years that the supervisors had been conducting their
respective modalities were minimal (CBT, 10.9 years [SD=11.0];
psychodynamic therapy, 9.7 years [SD=2.9]) but somewhat larger
with respect to mean years conducting supervision (CBT, 14.6
years [SD=10.3]; psychodynamic therapy, 6.3 years [SD=3.2]),
although neither difference was signiﬁcant.
Thirty-seven CBT therapists and 56 psychodynamic therapists
treated, on average, 4.2 patients (range, 1–16) and 3.0 patients
(range, 1–12), respectively. No differences between treatment
conditions were found with regard to the average number of times
a patient was discussed in supervision (CBT, 4.3; psychodynamic
therapy, 4.6) or the mean number of therapy sessions patients
received (CBT, 10.6; psychodynamic therapy, 10.9; mean numbers
are lower than the maximum of 16 because of premature
termination, dropout, and patients missing sessions). Regarding
therapist protocol adherence, CBT therapists reported a mean
score of 7.1 (scale range, 0–10) over 1,218 CBT sessions. Conditions
did not differ regarding the mean number of years of clinical
experience therapists had after completing their master’s degree
or medical degree (CBT, 7.5 years [SD=7.3]; psychodynamic ther-
apy, 7.4 years [SD=6.7]), but CBT was more often conducted by
psychologists, and psychodynamic therapy was more often con-
ducted by psychiatrists (x2=109.80, df=1, p,0.001). Furthermore,
CBT was conducted more often by a female therapist than was
psychodynamic therapy (x2=15.91, df=1, p,0.001). We therefore
conducted a sensitivity analysis controlling for therapist gender
and profession (psychologist, psychiatrist).
Patients with severe depression (HAM-D score .24) at base-
line (N=129) and those with moderate depression at baseline
who developed severe symptoms during psychotherapy mono-
therapy (N=21) were offered additional antidepressant medica-
tion administrated by a psychiatrist (who was not the patient’s
psychotherapist) according to a protocol starting with extended-
release venlafaxine at 75 mg/day, which could be increased to
a maximum dosage of 225 mg/day. In case of intolerance or non-
response, venlafaxine was switched to either citalopram or nor-
triptyline. Pharmacotherapy consultations addressed symptom
evaluation, side effects, and adherence. Three research psychia-
trists supervised pharmacotherapy.
Eight patients (6.2%) did not start the recommended pharma-
cotherapy, and 14 (10.8%) switched medication during treat-
ment. The number of patients not starting pharmacotherapy, the
pharmacotherapy dosages used, and patient-reported medica-
tion adherence did not differ signiﬁcantly between treatment
conditions.
Outcome Measures
The primary outcome measure was posttreatment remission
rate (HAM-D score #7). Secondary outcome measures included
1-year follow-up remission rates and posttreatment and follow-
up observer-rated (HAM-D) and patient-rated mean depression
scores (Inventory of Depressive Symptomatology–Self-Report
[IDS-SR] [25]).
Trained research assistants (master’s-level graduate students
in clinical psychology) assessed the HAM-D according to the Dutch
scoring manual (26). Assessors participated in biweekly 1-hour
peer supervision sessions, in which audiotaped interviews were
discussed. The average intraclass correlation coefﬁcient over 46
audiotaped assessments scored by multiple assessors was 0.97.
Both observer- and patient-rated depression measures showed
good reliability at baseline assessment (Cronbach’s alpha: observer-
rated, 0.75; patient-rated, 0.78). HAM-D assessors were not blind
to treatment condition. We therefore requested the assessors’ hy-
potheses regarding treatment effects at the posttreatment and follow-
up assessments and conducted a sensitivity analysis controlling
for these variables.
Randomization
Separate random allocation sequences were generated for
each of the three clinics by one of the authors (J.P.) using the
SPSS random number generator (SPSS, Chicago). Randomization
was stratiﬁed by gender and age (,32.5 years and .32.5 years).
Research assistants, aware of the allocation sequence, enrolled
participants and assigned them to interventions.
Statistical Methods
Analyses were based on an intent-to-treat sample, including
all patients randomly assigned. Patients were considered drop-
outs if they completed less than eight psychotherapy sessions.
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Response was deﬁned as a reduction in HAM-D scores $50% at
posttreatment.
Given the hierarchical data structure, linear mixed-model an-
alyses were used for continuous outcomes, and logistic generalized
estimating equation analyses were used for dichotomous out-
comes. These analyses were preferred over logistic mixed-model
analyses because of the instability of the latter (27). In examining
pre- to posttreatment outcomes, we excluded follow-up data (for
which additional help-seeking could not be controlled) from the
analyses. Mixed-model analyses were conducted according to
a three-level structure (therapist, patient, and repeated measures).
Location (clinic) was included as a covariate in a sensitivity
analysis, rather than as a level because of the small number of
categories (N=3). Mixed-model analyses were performed with
MLwiN, version 2.22 (http://www.bristol.ac.uk/cmm/software/
mlwin). All other analyses were performed with SPSS, version 16.0.
We started with a basic model including main effects for
treatment and time and a time-by-treatment interaction. Time
was treated as a categorical variable to assess treatment effects at the
different time points. To control for possible confounders, we next
added the following sets of covariates: 1) clinic and number of
patients with a baseline HAM-D score .24; 2) demographic
characteristics (as listed in Table 1); 3) depression characteristics
(as listed in Table 1); 4) therapist gender and profession; 5) the HAM-
D assessors’ treatment outcome hypotheses; and 6) help-seeking
during the follow-up period (as reported in Table S1 in the data
supplement that accompanies the online edition of this article). The
estimated main effects for treatment at different assessment points
under these different models are reported as odds ratios with 95%
conﬁdence intervals for remission rates and differences in means for
continuous outcomes. For the latter, we also calculated effect sizes
(Cohen’s d) and 95% conﬁdence intervals using Comprehensive
Meta-Analysis, version 2.2.046 (Biostat, Englewood, N.J.).
We then used a two-step strategy for the interpretation of
outcomes. First, we examined whether treatment outcomes
differed signiﬁcantly. We considered treatment differences to
be nonsigniﬁcant if the 95% conﬁdence interval included 1.00 or
0.00 for odds ratios and effect sizes, respectively. This constituted
our primary research question. Second, when differences were
nonsigniﬁcant, we next examined whether psychodynamic
therapy was noninferior to CBT by comparing outcomes to pre-
speciﬁed noninferiority margins. These margins were deter-
mined based on the expert opinion of 10 experienced depression
research clinicians (unaware of preliminary trial results) who
rated a difference of 10% for remission rates and 2.6 HAM-D
points (equivalent to a Cohen’s d value of 0.30) as the maximum
difference allowable to conclude noninferiority. Based on a
maximum difference of 10% (remission rates of 12% and 22%),
noninferiority margins for remission were set at an odds ratio of
0.49. For all continuous outcomemeasures, noninferiority margins
were prespeciﬁed at a Cohen’s d value of 0.30. We compared the
95% conﬁdence intervals of the effect sizes and odds ratios with
the above-mentioned prespeciﬁed noninferiority margins and
considered psychodynamic therapy noninferior to CBT on a given
outcome measure if the 95% conﬁdence interval limit did not
exceed the prespeciﬁed noninferiority margin for that measure.
This constituted our secondary research question. We repeated the
main analyses in the subgroup of moderately depressed patients
(HAM-D score #24) receiving psychotherapy only and in the
subgroup of severely depressed patients (HAM-D score .24)
receiving combined psychotherapy and pharmacotherapy in order
to investigate whether pooling these subgroups may have obscured
differential patterns of results.
Power Analysis
An a priori power analysis (14) indicated that 300 participants
were required (alpha=0.05, 12b=0.80) to answer our primary
research question. To detect the 10% difference in remission
rates between conditions that constituted the noninferiority margin
(alpha=0.05, 12b=0.80), 344 participants were needed (using SPSS
SamplePower for equivalence studies, one-tailed). Power to detect
an outcome difference of a Cohen’s d value of 0.30 for continuous
outcome measures was 0.87.
Results
Participants
The CONSORT diagram for the study is presented in
Figure 1. FromApril 2006 to December 2009, 4,866 patients
were assessed for eligibility during a standard intake pro-
cedure; 570 (11.7%) were found to be potentially eligible
and invited for baseline assessment. Of these patients, 229
(40.2%) did not meet inclusion criteria or were not willing
to participate. Therefore, 341 patients were randomly as-
signed to CBT (N=164) or psychodynamic therapy (N=177).
Demographic and clinical characteristics of the sample are
summarized in Table 1. No signiﬁcant differences were
found between the two treatment conditions.
No signiﬁcant differences were found between treat-
ment conditions regarding the proportion of patients who
did not complete treatment (CBT, 31.1%; psychodynamic
therapy, 25.9%). Themajority of patients who dropped out
were those who missed treatment appointments without
specifying a reason (53.9%). Recruitment was discontinued
when the intended number of participants was reached.
One-year follow-up assessments were conducted from
April 2007 to January 2011.
Posttreatment Outcomes
Based on observed data, 24.3% (N=27/111) of the patients
in the CBT condition and 21.3% (N=26/122) in the psycho-
dynamic therapy conditionmet the remission criterion at the
posttreatment assessment. Observed response rates were
38.7% (N=43/111) for CBT and 36.9% (N=45/122) for
psychodynamic therapy. Estimated odds ratios for remission
at different assessment points are listed in Table 2. At the
posttreatment assessment, the odds ratio was 0.82 (95%
CI=0.45–1.50), indicating that remission rates did not differ
signiﬁcantly. The lower limit of the odds ratio’s 95%
conﬁdence interval exceeded the prespeciﬁed noninferiority
margin of 0.49. This pattern of results did not change when
different sets of covariates were added (Table 2).
Mean observer- and patient-rated depression scores
during treatment for both groups are presented in Figure 2;
depressive symptom scores in both conditions improved
over time. Estimated observer- and patient-rated mean
differences at different assessment points are presented in
Table 2, along with effect sizes of the posttreatment dif-
ferences between conditions. At week 22, the estimated
observer-rated difference between treatment conditions
was 0.24 points (SE=0.90) on the HAM-D, corresponding with
an effect size (Cohen’s d) of 0.02 (95% CI=20.24 to 0.27),
indicating that treatment differences were nonsigniﬁcant.
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TABLE 1. Baseline Demographic and Clinical Characteristics of Participants in a Study of the Efﬁcacy of Psychodynamic
Therapy Relative to Cognitive-Behavioral Therapya
Characteristic Total Sample (N=341) CBT Group (N=164)
Psychodynamic Therapy
Group (N=177)
Demographic
Mean SD Mean SD Mean SD
Age (years) 38.91 10.30 38.27 10.13 39.49 10.44
N % N % N %
Gender
Male 102 29.9 51 31.1 51 28.8
Female 239 70.1 113 68.9 126 71.2
Cultural background
Northwest European 186 55.0 92 56.1 94 54.0
Other 152 44.9 72 43.9 80 46.0
Marital status
Married 80 23.7 45 27.4 35 20.1
Divorced 69 20.4 34 20.7 35 20.1
Widowed 10 3.0 4 2.4 6 3.4
Never married 176 52.1 80 48.8 96 55.2
Other 3 0.9 1 0.6 2 1.1
Living situation
Living with at least one other person 220 65.3 110 67.1 110 63.6
Living alone 106 31.5 51 31.1 55 31.8
Other 11 3.3 3 1.8 8 4.6
Job status
Currently working 130 38.8 61 37.4 69 40.1
Receiving sickness beneﬁts 55 16.4 35 21.5 20 11.6
Receiving social security beneﬁts 74 22.1 34 20.9 40 23.3
Receiving disability beneﬁts 32 9.6 13 8.0 19 11.0
Student 14 4.2 5 3.1 9 5.2
Other 30 9.0 15 9.2 15 8.7
Education level
Low 67 20.0 35 21.5 32 18.6
Intermediate 159 47.5 71 43.6 88 51.2
High 101 30.1 55 33.7 46 26.7
Other 8 2.4 2 1.2 6 3.5
Main income before taxes
#€1,273 a month 113 42.8 49 37.4 64 48.1
$€1,274 a month 151 57.2 82 62.6 69 51.9
Symptom severity
HAM-D score .24 129 37.8 66 40.2 63 35.6
Mean SD Mean SD Mean SD
HAM-D score 23.40 5.35 23.68 5.47 23.14 5.24
Patient-rated depression score 42.73 11.00 42.88 10.08 42.60 11.82
N % N % N %
Comorbid axis I disorderb
No 204 59.8 98 59.8 106 59.9
Yes 137 40.2 66 40.2 71 40.1
Depression
Duration present episode
,6 months 84 25.1 48 29.8 36 20.8
6 months–1 year 88 26.3 43 26.7 45 26.0
1–2 years 43 12.9 22 13.7 21 12.1
.2 years 86 25.7 35 21.7 51 29.5
Unknown 33 9.9 13 8.1 20 11.6
Previous treatment for current depressive episode
No 218 65.3 100 62.1 118 68.2
Yes 116 34.7 61 37.9 55 31.8
continued
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The estimated patient-rated difference between treatment
conditions was 1.94 points (SE=1.92) on the IDS-SR,
correspondingwith an effect size of20.08 (95%CI=20.38 to
0.22), also indicating that differences were not signiﬁcant.
The upper limits of the 95% conﬁdence intervals for both
effect sizes did not exceed the prespeciﬁed noninferiority
margin of 0.30. This pattern of results did not change when
controlling for different covariates, although the noninferiority
margin was slightly exceeded when controlling for clinic
and number of patients with baseline HAM-D scores .24
(HAM-D estimated mean difference=0.64 [SE=0.81]; Cohen’s
d=0.05, 95% CI=20.21 to 0.31).
In the moderately depressed subgroup, observed re-
mission rates for CBT and psychodynamic therapy were
26.5% (N=18/68) and 27.7% (N=23/83), respectively, with
estimated odds ratios (1.02, 95% CI=0.50–2.06), observer
ratings (Cohen’s d=–0.05, 95% CI=–0.37 to 0.27), and
patient ratings (Cohen’s d=–0.24, 95% CI=–0.61 to 0.13)
all indicating that psychodynamic therapy was noninferior
to CBT. In the severely depressed subgroup receiving
additional pharmacotherapy, observed remission rates for
CBT and psychodynamic therapy were 20.9% (N=9/43)
and 7.7% (N=3/39), respectively, with estimated odds
ratios (0.31, 95% CI=0.08–1.26), observer ratings (Cohen’s
d=0.21, 95% CI=–0.23 to 0.64), and patient ratings (Cohen’s
d=0.17, 95% CI=–0.35 to 0.69) all indicating no signiﬁcant
differences, without demonstrating noninferiority of psy-
chodynamic therapy relative to CBT.
Follow-Up Outcomes
Follow-up assessments were conducted with 192 (56.3%)
participants (Figure 1). More patients reported having
received additional treatment during the follow-up period
in the CBT condition (N=41 [44.6%]) than in the psycho-
dynamic therapy condition (N=32 [33.0%]), but this differ-
ence did not reach signiﬁcance (x2=2.67, df=1, p=0.10) (see
Table S1 in the online data supplement).
Based on observed data, 34.7% (N=33/95) of patients in
the CBT condition and 26.8% (N=26/97) of those in the
psychodynamic therapy condition met the remission
criterion. The estimated odds ratio of remission rates at
follow-upwas 0.74 (95%CI=0.41–1.34) (Table 3), indicating
that remission rates did not differ signiﬁcantly. The lower
limit of the odds ratio’s 95% conﬁdence interval exceeded
the prespeciﬁed noninferioritymargin of 0.49. This pattern
of results did not change when different sets of covariates
were added.
Estimated observer- and patient-ratedmean differences
at follow-up and corresponding effect sizes are presented
in Table 3. The estimated observer-rated difference
between treatment conditions was 1.94 points (SE=1.01)
on the HAM-D (Cohen’s d=0.14, 95% CI=20.14 to 0.42),
and the estimated patient-rated difference was 2.99 points
(SE=2.22) on the IDS-SR (Cohen’s d=0.12, 95% CI=20.23 to
0.48), both indicating that treatment differences were not
signiﬁcant. The upper limits of the 95% conﬁdence
intervals for both effect sizes exceeded the prespeciﬁed
noninferiority margin of 0.30. This pattern of results did
not change when controlling for different covariates.
In the moderately depressed subgroup, observed re-
mission rates were 40.0% (N=22/55) in the CBT condition
and 35.4% (N=23/65) in the psychodynamic therapy
condition (odds ratio=0.84, 95% CI=0.41–1.73; observer
rated: Cohen’s d=0.08, 95%CI=20.28 to 0.44; patient rated:
Cohen’s d=0.02, 95% CI=20.40 to 0.45). In the severely
depressed subgroup receiving additional pharmacother-
apy, observed remission rates were 27.5% (N=11/40) for
CBT and 9.4% (N=3/32) for psychodynamic therapy (odds
ratio=0.27, 95% CI=0.07–1.08; observer rated: Cohen’s
d=0.32, 95% CI=20.15 to 0.79; patient rated: Cohen’s
d=0.40, 95% CI=20.27 to 1.07). All these differences were
nonsigniﬁcant, but noninferiority could not be demon-
strated for any of them.
Adverse Events
Serious adverse events during treatment and follow-up
were mostly increases in depressive symptoms or suici-
dality for which additional treatment was needed (see
Table S2 in the online data supplement). No differences
were found between the treatment conditions with regard
to the proportion of patients reporting serious adverse
events during treatment (CBT, 6.1%; psychodynamic
therapy, 6.2%) or follow-up (CBT, 1.8%; psychodynamic
therapy, 2.3%).
TABLE 1. Baseline Demographic and Clinical Characteristics of Participants in a Study of the Efﬁcacy of Psychodynamic
Therapy Relative to Cognitive-Behavioral Therapya (continued)
Characteristic Total Sample (N=341) CBT Group (N=164)
Psychodynamic Therapy
Group (N=177)
Number of previous depressive episodes
None 103 31.1 55 34.6 48 27.9
One 69 20.8 29 18.2 40 23.3
Two or more 159 48.0 75 47.2 84 48.8
Comorbid dysthymia
No 194 66.0 94 68.1 100 64.1
Yes 100 34.0 44 31.9 56 35.9
a CBT=cognitive-behavioral therapy; HAM-D=Hamilton Depression Rating Scale.
b Comorbid axis I disorders were assessed by the psychotherapists during treatment without the use of a structured interview, and comorbidity
rates may therefore be underestimated.
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Discussion
Weused a randomized clinical design and noninferiority
margins to compare the efﬁcacy of CBT and psychody-
namic therapy for major depression in a large sample of
patients treated in psychiatric outpatient clinics. Primary
analyses indicated no signiﬁcant differences between
treatment conditions at the posttreatment assessment.
In secondary analyses, noninferiority could not be dem-
onstrated for posttreatment remission rates but was dem-
onstrated for posttreatment patient- and observer-rated
depression scores. Follow-up ﬁndings again showed no sig-
niﬁcant differences between treatments, but noninferiority
FIGURE 1. CONSORT Diagram of Participants in a Study of the Efﬁcacy of Psychodynamic Therapy Relative to Cognitive-
Behavioral Therapya
Enrollment Assessed for eligibility during 
standard intake procedure 
(N=4,866)
Research baseline assessment 
(N=570)
Randomization
(N=341)
Allocated to CBT (N=164)
HAM-D score >24 receiving additional pharmaco-
therapy (N=66) 
Did not start therapy (N=8) 
Started therapy (N=156)
• Completed <8 sessions (N=43)
• Completed ≥8 sessions (N=113)
Allocated to psychodynamic therapy (N=177)
HAM-D score >24 receiving additional pharmaco-
therapy (N=63) 
Did not start therapy (N=11) 
Started therapy (N=166)
• Completed <8 sessions (N=35)
• Completed ≥8 sessions (N=131)
Allocation
Excluded (N=4,296)
• Primary diagnosis not depression (N=3,457)
• Use of efficacious antidepressants that could not 
be tapered (N=292)
• Unable to fill in questionnaires because of 
language problems (N=182)
• Alcohol/substance use or misuse (N=147)
• Unable to meet research demands (N=80)
• Other reasons, e.g., pregnancy, suicide risk (N=138)
Excluded (N=229)
• Declined to participate (N=73)
• HAM-D score <14 (N=49)
• Did not meet MINI-Plus criteria for depressive 
episode (N=8) 
• Not meeting other inclusion criteria (N=76)
• Referred to other research project (N=23)
Lost to HAM-D assessment (N=69)
• Week 5 (N=23) 
• Week 10 (N=14)
• Week 22 (N=10)
• Week 52 (N=22)
Lost to HAM-D assessment (N=80)
• Week 5 (N=36)
• Week 10 (N=7)
• Week 22 (N=8)
• Week 52 (N=29)
Analyzed
• Intent-to-treat (N=164)
Analyzed
• Intent-to-treat (N=177)
Follow-Up
Analysis
a CBT=cognitive-behavioral therapy; HAM-D=Hamilton Depression Rating Scale; MINI-Plus=Mini-International Neuropsychiatric
Interview–Plus.
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could not be demonstrated for any of the three outcome
measures. However, the follow-up ﬁndings must be inter-
preted with caution because of a nonsigniﬁcant result sug-
gesting that patients in the CBT condition received more
additional treatment during the follow-up period. Our ﬁnd-
ings are in line with previous meta-analyses (9, 11, 28) that
reported no signiﬁcant differences between individual CBT
and psychodynamic therapy at posttreatment assessments.
Post hoc analyses revealed no signiﬁcant differences
between treatment conditions in the subgroup of moder-
ately depressed patients receiving psychotherapy only, and
noninferiority of psychodynamic therapy relative to CBT
was shown for all posttreatment outcome measures in this
group of patients. These ﬁndings add to the evidence base
of psychodynamic therapy for depression. No signiﬁcant
differences between treatments were found in the sub-
group of severely depressed patients receiving combined
treatment, but differences were large enough to be signif-
icant if replicated in a larger sample, and noninferiority
could not be concluded in this group.
One notable ﬁnding was that only 22.7% of the patients
achieved remission at posttreatment, with 40% seeking
additional treatment afterward. These remission rates are
lower than those found in previous trials examining either
short-term psychodynamic supportive psychotherapy (22)
or CBT (29, 30). This difference may be related to the
relatively low socioeconomic status and income levels in
our sample, which in naturalistic studies have been iden-
tiﬁed as predictors for less favorable treatment response
(31, 32), or to the relatively high rate of comorbid axis I
disorders. Our ﬁndings indicate that a substantial pro-
portion of patients in specialized second-line outpatient
clinics require more than time-limited treatment to
achieve remission. These results are in line with ﬁndings
TABLE 2. Treatment Effects at Different Assessment Points According to the Basic Model of Analysis and When Corrected for
Different Sets of Covariatesa
Time and Model
Remission HAM-D Score IDS-SR Score
Odds Ratio 95% CI
Estimated Mean
Difference Effect Size
Estimated Mean
Difference Effect Size
Difference SE Cohen’s d 95% CI Difference SE Cohen’s d 95% CI
Week 0
Model 1 –0.55 0.78 –0.31 1.62
Model 2 –0.21 0.69 0.35 1.51
Model 3 –0.65 0.77 –0.40 1.55
Model 4 –0.42 0.80 0.05 1.63
Model 5 –0.88 0.95 –1.33 1.98
Model 6 –0.56 0.79 –0.29 1.64
Week 5
Model 1 0.61 0.19–1.98 0.46 0.88
Model 2 0.58 0.18–1.87 0.79 0.79
Model 3 0.52 0.17–1.65 0.30 0.87
Model 4 0.44 0.13–1.55 0.68 0.89
Model 5 0.65 0.19–2.25 0.11 1.03
Model 6 0.62 0.19–2.03 0.58 0.89
Week 10
Model 1 1.26 0.58–2.77 1.00 0.89 1.34 1.85
Model 2 1.22 0.56–2.66 1.34 0.81 1.74 1.74
Model 3 1.13 0.50–2.59 0.92 0.88 1.32 1.79
Model 4 1.11 0.49–2.50 1.22 0.91 1.95 1.85
Model 5 1.35 0.56–3.22 0.64 1.05 0.25 2.19
Model 6 1.31 0.60–2.85 0.83 0.91 1.04 1.87
Week 22
Model 1 0.82 0.45–1.50 0.24 0.90 0.02 –0.24 to 0.27 –1.94 1.92 –0.08 –0.38 to 0.22
Model 2 0.78 0.42–1.43 0.64 0.81 0.05 –0.21 to 0.31 –1.60 1.82 –0.07 –0.37 to 0.23
Model 3 0.70 0.36–1.38 0.14 0.89 0.01 –0.25 to 0.27 –1.92 1.88 –0.08 –0.38 to 0.22
Model 4 0.72 0.38–1.35 0.36 0.91 0.03 –0.23 to 0.28 –2.04 1.93 –0.08 –0.38 to 0.22
Model 5 0.89 0.41–1.93 –0.12 1.05 –0.01 –0.26 to 0.25 –2.99 2.26 –0.10 –0.40 to 0.20
Model 6 0.83 0.45–1.53 0.31 0.91 0.02 –0.24 to 0.28 –1.96 1.94 –0.08 –0.38 to 0.23
a HAM-D5Hamilton Depression Rating Scale; IDS-SR5Inventory of Depressive Symptomatology–Self Report. Model 1 is the basic model
including a main effect for treatment and time and a time-by-treatment interaction; model 2 is the basic model with clinic and number of
patients with baseline HAM-D scores .24 added as covariates; model 3 is the basic model with demographic characteristics (as listed in
Table 1) added as covariates; model 4 is the basic model with depression characteristics (as listed in Table 1) added as covariates; model 5 is
the basic model with therapist gender and profession added as covariates; and model 6 is the basic model with HAM-D assessors’
hypotheses regarding treatment outcomes added as a covariate.
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regarding psychotherapy in real-world clinical practice
(33) and show that depression as it is encountered in
secondary care can be characterized as a difﬁcult-to-treat
disorder. Since residual depressive symptoms have been
found to be the main predictor of future relapse (34), our
ﬁndings also indicate that psychotherapeutic treatment
needs to be improved. The ﬁndings suggest that clinicians
and policymakers should be realistic about the expected
outcome of time-limited depression treatments and
should bear in mind that mandated limits on treatment
duration may lead to undertreatment of depression.
Strengths and Limitations
This study has a number of strengths. First, several ele-
ments contribute to the generalizability of the study’s
ﬁndings. Treatment was provided in regular psychiatric
outpatient clinics by a large number of therapists with
different experience levels. Patients were not recruited by
advertisement but instead were referred by general prac-
titioners, and no selection criteria with regard to previous
treatment or suitability for psychotherapy were applied.
Patients with relatively low socioeconomic status were
included, and almost one-half of the patient sample
reported a non-Northwest European (immigrant) cultural
background. Second, we included severely depressed
patients who were additionally treated with pharmaco-
therapy prescribed according to a protocol. Third, this is,
to our knowledge, the largest randomized controlled trial
to date comparing CBT and psychodynamic therapy in the
treatment of depression (N=341). By comparison, a meta-
analysis of psychodynamic therapy for depression included
a total of 421 patients across six CBT-psychodynamic
randomized controlled trials (9). Finally, this was the ﬁrst
study to test whether psychodynamic therapy can be
demonstrated to be noninferior to CBT in the treatment
of depression.
This study also has a number of limitations. First, a
substantial number of patients did not complete treat-
ment or were lost to assessment. Second, treatment ﬁ-
delity was not systematically assessed but was instead
checked bymeans of intensive supervision by experienced
supervisors and subjective therapist ratings. These ratings
suggested adequate adherence to the CBT manual, but no
suchmeasure was available for psychodynamic treatment.
Third, HAM-D assessors were not blind to treatment
condition, and therefore we cannot rule out observer bias.
However, controlling for assessor-rated treatment expect-
ations did not alter the pattern of results, and results were
similar for observer- and patient-rated outcomes. Fourth,
research assistants enrolling participants were aware of
the allocation sequence, which may have introduced
selection bias. However, no signiﬁcant differences were
found with regard to any of the sample baseline character-
istics. Fifth, although noninferioritymargins were carefully
thought through and based on clinical expert opinion,
they were still set in an arbitrary fashion. Sixth, we could
not prevent patients from seeking additional treatment
during the follow-up period, and a nonsigniﬁcant ﬁnding
suggested that patients in the CBT group may have
returned to treatment more than those in the psychody-
namic therapy group. However, controlling for additional
treatment in the follow-up period did not change the
general pattern of results. Finally, the study did not include
a control condition.
Conclusions
No statistically signiﬁcant differences were found be-
tween psychodynamic therapy and CBT in a large sample
FIGURE 2. Observer-Rated and Patient-Rated Mean Depres-
sion Scores During Treatmenta
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a CBT=cognitive-behavioral therapy; HAM-D=Hamilton Depression
Rating Scale; IDS-SR=Inventory of Depressive Symptomatology–Self
Report.
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of patients treated for a major depressive episode, and less
than one-fourth of the patients reached remission within
22 weeks of treatment. Noninferiority of psychodynamic
therapy relative to CBT was demonstrated for posttreat-
ment mean depression scores but could not be demon-
strated for remission rates and follow-up measures. Our
ﬁndings extend the evidence base of psychodynamic
therapy for depression but also indicate that time-limited
psychotherapy is not sufﬁcient for a substantial number of
patients encountered in psychiatric outpatient clinics.
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Clinical Guidance: Comparison of CBT and Psychodynamic
Therapy for Depression
Cognitive-behavioral therapy (CBT) and short-term psychodynamic psychother-
apy provide similar outcomes for patients with a major depressive episode, but
remission rates at the end of treatment are low for both treatments. The rates in
the trial by Driessen et al. were less than 25% for patients referred to psychiatric
clinics, who may be more difﬁcult to treat than most primary care depressed
patients. However, emphasizes Thase in an editorial (p. 953), the similarity in
outcomes adds to the evidence for using both psychodynamic psychotherapy
and CBT with depressed outpatients.
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